A detailed history of Captrust Financial Advisors transactions in Siga Technologies Inc stock. As of the latest transaction made, Captrust Financial Advisors holds 11,036 shares of SIGA stock, worth $83,211. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,036
Previous 11,104 0.61%
Holding current value
$83,211
Previous $95,000 12.63%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$6.32 - $10.46 $429 - $711
-68 Reduced 0.61%
11,036 $83,000
Q1 2024

May 15, 2024

SELL
$4.51 - $8.92 $4 - $8
-1 Reduced 0.01%
11,104 $95,000
Q4 2023

Feb 14, 2024

BUY
$4.82 - $6.25 $645 - $837
134 Added 1.22%
11,105 $62,000
Q3 2023

Nov 14, 2023

SELL
$4.32 - $5.77 $1,054 - $1,407
-244 Reduced 2.18%
10,971 $57,000
Q2 2023

Aug 14, 2023

BUY
$5.0 - $6.31 $325 - $410
65 Added 0.58%
11,215 $56,000
Q1 2023

May 15, 2023

BUY
$5.23 - $8.42 $58,314 - $93,883
11,150 New
11,150 $64,000
Q3 2022

Nov 16, 2022

BUY
$10.02 - $26.15 $110,360 - $288,016
11,014 Added 1160.59%
11,963 $123,000
Q2 2022

Aug 23, 2022

SELL
$6.5 - $13.68 $81,991 - $172,559
-12,614 Reduced 93.0%
949 $11,000
Q2 2022

Aug 16, 2022

BUY
$6.5 - $13.68 $86,931 - $182,956
13,374 Added 7076.19%
13,563 $157,000
Q1 2022

May 16, 2022

SELL
$5.96 - $7.61 $184 - $235
-31 Reduced 14.09%
189 $1,000
Q4 2021

Feb 14, 2022

BUY
$6.96 - $9.26 $90 - $120
13 Added 6.28%
220 $2,000
Q1 2021

May 17, 2021

SELL
$6.3 - $7.71 $163,529 - $200,128
-25,957 Reduced 99.21%
207 $1,000
Q4 2020

Feb 16, 2021

BUY
$6.39 - $7.76 $167,187 - $203,032
26,164 New
26,164 $190,000

Others Institutions Holding SIGA

About SIGA TECHNOLOGIES INC


  • Ticker SIGA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 73,024,096
  • Market Cap $551M
  • Description
  • SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla T...
More about SIGA
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.